NUS Researchers Identify Potential Target for Treatment of Aggressive Brain Cancer
Researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore have discovered that the BCL6 protein could potentially be used as a marker to predict clinical outcomes of patients suffering from Glioblastoma Multiforme (GBM), the most malignant cancer of the brain. Specifically, the study, led by Professor H. Phillip Koeffler, senior principal investigator at CSI Singapore, found that GBM patients with lower levels of the BCL6 protein have a higher survival rate than those with high BCL6 expression. The study also suggests BCL6 as a possible target for GBM treatment – controlling the levels and activities of the BCL6 protein could potentially contribute to treatment of the disease. GBM is aggressively cancerous as the cells reproduce rapidly and spread extensively in the brain and is also highly resistant to conventional therapy. This makes treatment exceptionally tough and challenging. GBM patients usually survive less than 15 months after diagnosis.
Click here to read more.
The New England Master Class - Anterior Skull Base Surgery
May 20-21, 2019; Boston
6th Annual Meeting on Neurosurgery and Neurologica
May 22-23, 2019; London
INS 14th World Congress
May 25-30, 2019; Sydney
12th Annual Cervical Spine Research Society Hands-on Cadaver Course
May 30-June 1, 2019; St. Louis
Brain Tumor Biotech Summit
June 7, 2019; New York